Canadian Center for Vaccinology
15
2
4
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
27%
4 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies
Role: collaborator
Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
Role: collaborator
Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
Role: collaborator
Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart
Role: collaborator
Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness
Role: collaborator
Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV
Role: collaborator
Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity
Role: collaborator
Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction
Role: collaborator
Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
Role: collaborator
CT18 Infant Influenza Priming Study in Vaccine Naive Infants
Role: collaborator
Adolescent MenACWY Booster Study
Role: collaborator
Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada
Role: collaborator
A Randomized Controlled Trial of the Effectiveness of the Ottawa Influenza Decision Aid
Role: collaborator
Oseltamivir Pharmacokinetics in Morbid Obesity
Role: collaborator
Cluster RCT - Evaluating Effectiveness of a Guide and Tools for Influenza Immunization Campaign Planners
Role: collaborator
All 15 trials loaded